Lundbeck
HLUN-B.CO
#2582
Rank
C$7.72 B
Marketcap
$8.10
Share price
-0.98%
Change (1 day)
28.41%
Change (1 year)
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.

P/E ratio for Lundbeck (HLUN-B.CO)

P/E ratio as of December 2024 (TTM): 15.9

According to Lundbeck 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 15.8791. At the end of 2022 the company had a P/E ratio of 13.6.

P/E ratio history for Lundbeck from 2022 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202213.6

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.